Explore the Adbry Virtual Booth: Visit Now
- Tralokinumab-ldrm is a human IgG4 monoclonal antibody that specifically binds to human interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits (IL-13Rα1 and IL-13Rα2)1,2
- IL-13 is a naturally occurring cytokine of the Type 2 immune response. Tralokinumab-ldrm inhibits the bioactivity of IL-13 by blocking IL-13 interaction with IL-13Rα1/IL-4Rα receptor complex. Tralokinumab-ldrm inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines, and IgE1
Adbry is a targeted biologic therapy and is not an
immunosuppressant or a steroid.1,3
Watch MOA video
PHARMACODYNAMICS1
Adbry:
- Was associated with decreased concentrations of Th2 and Th22 immunity biomarkers in the blood, such as thymus and activation-regulated chemokine (TARC/CCL17), periostin, IL-22, lactate dehydrogenase (LDH) and serum IgE
- Decreased expression of keratin 16 and Ki-67 in atopic dermatitis skin
- Upregulated protein expression of loricrin suppressed expression of genes in the Th2 pathway, including CCL17, CCL18, and CCL26, as well as markers of Th17- and Th22-regulated genes in lesional skin
The clinical relevance of these biomarkers is not fully understood.
DESCRIPTION
- Tralokinumab-ldrm, an interleukin-13 antagonist, is a human IgG4 monoclonal antibody. Tralokinumab-ldrm is produced in mouse myeloma cells by recombinant DNA technology, consists of 1326 amino acids, and has a molecular weight of approximately 147 kilodaltons
- Adbry (tralokinumab-ldrm) injection is a sterile, preservative-free, clear to opalescent, colorless to pale yellow solution for subcutaneous use supplied as a single-dose prefilled syringe with needle guard in a siliconized Type-1 clear glass syringe. None of the components of the prefilled syringe or the needle guard are made with natural rubber latex
- Each prefilled syringe delivers 150 mg Adbry in 1 mL and the inactive ingredients: acetic acid (0.3 mg), polysorbate 80 (0.1 mg), sodium acetate trihydrate (6 mg), sodium chloride (5 mg), and Water for Injection, at an approximate pH of 5.5
Review Adbry Clinical Study Results
References: 1. Popovic B, Breed J, Rees DG, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. J Mol Biol. 2017;429(2):208-219. 2. Adbry Prescribing Information, LEO Pharma. 3. Immunosuppressants. National Eczema Association website. https://nationaleczema.org/eczema/treatment/immunosuppressants/. Accessed March 4, 2021.